Research Article |
Corresponding author: Dmitry I. Pozdnyakov ( pozdniackow.dmitry@yandex.ru ) Academic editor: Mikhail Korokin
© 2022 Dmitry I. Pozdnyakov, Zhanna V. Dayronas, Denis S. Zolotych, Anastasya D. Geraschenko, Natalya B. Shabanova.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Pozdnyakov DI, Dayronas ZV, Zolotych DS, Geraschenko AD, Shabanova NB (2022) Neuroprotective effects of a 40% ethanol extract of the black walnut bark (Juglans nigra L.). Research Results in Pharmacology 8(2): 59-68. https://doi.org/10.3897/rrpharmacology.8.77172
|
Introduction: Neuroprotection is a promising area of adjuvant therapy of ischemic brain lesions. At the same time, among potentially effective neuroprotectors, herbal remedies are distinguished due to their high efficiency and safety of use. In this work, some aspects of the neuroprotective effect of 40% ethanol extract of black walnut bark were investigated in comparison with its major component juglone.
Materials and methods: The work was performed on male Wistar rats, which were simulated with cerebral ischemia by irreversible occlusion of the middle cerebral artery. The acute toxicity of the extract was preliminarily evaluated. During the work, the following parameters were determined: changes in the behavior of animals in the Morris water maze, cerebral blood flow, brain necrosis zone area, the activity of mitochondrial complexes, citrate synthase activity, lactic, pyruvic, and ATP concentrations. The activity of the studied extract was compared with juglone in a concentration of 1 mg/kg (per os).
Discussion: The study showed that the use of black walnut bark extract in conditions of cerebral ischemia contributed to an increase in the activity of mitochondrial complexes I-V, citrate synthase, which in turn led to the normalization of aerobic-anaerobic metabolism reactions. The increase in the activity of respiratory complexes is probably mediated by the antioxidant properties of juglone, which is a major component of the test extract of black walnut bark.
Conclusion: Thus, the test extract can be a potentially effective neuroprotective agent and requires further study.
Juglans nigra extract, cerebral ischemia, neuroprotection, mitochondrial dysfunction.
According to the latest statistics from the World Health Organization, ischemic brain lesions and, in particular, ischemic stroke, remain one of the main causes of death, with a high level of primary disability in the population. More than 50 million cases of ischemic stroke are reported annually. More than half are fatal in the acute phase of the disease (
Juglans nigra L. of the Juglandaceae family is a widespread deciduous tree that grows mainly in temperate climates. In ethnomedicine, the leaves of Juglans nigra L. are used as an antispasmodic and antidiarrheal agent. Recent studies have shown that extracts derived from Juglans nigra L. raw materials are characterized by a broad spectrum of pharmacological activities, including antimicrobial, antioxidant, and anti-inflammatory properties (
Aim of the study: To evaluate the neuroprotective potential of an ethanolic extract of black walnut bark on a model of permanent occlusion of the middle cerebral artery in rats.
The work was performed on 80 male Wistar rats weighing 200–220 grams, 3 months old, and 8 sexually mature male Balb/c mice weighing 20–22 grams. The animals were obtained from the Rappolovo Nursery (Leningrad region, Russia) and during the experiment were kept under controlled conditions in the Laboratory of Living Systems at Pyatigorsk Medical and Pharmaceutical Institute. The conditions of animal housing: ambient temperature of +22±2 °C, relative humidity of 60±5%, with a 12-hour dar-light cycle. The rats were housed by 5 animals in macrolon cages with granular cellulose bedding with free access to water and food. The study was carried out according to the recommendations of Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes, of September 22, 2010, and ARRIVE guidelines (
As a test object, we used a standardized extract of black walnut bark obtained by extraction with 40% ethanol in a Soxhlet apparatus for 48 hours, followed by evaporation in a vacuum evaporator. The resulting dry residue was dissolved in purified water. Walnut bark was collected in the autumn in the Caucasian Mineral Waters region (44°3'13"N, 43°5'18"E), herbarium sample No. 217. The test extract was obtained and standardized according to the scheme described in patent RU 2 608 026 C1 and characterized by the content of berberine, juglone, juglandin, vitamin C, sitosterol, and betulin. As a comparison, juglone (Sigma-Aldrich) at a dose of 1 mg/kg (
At the first stage of the study, the toxicity of the test extract was evaluated in an acute experiment, according to the protocol of the experimental procedure “Up and Down” in the Balb/c mice. Next, the neuroprotective potential of the black walnut bark was assessed on the model of permanent occlusion of the middle cerebral artery in rats. At the same time, the following experimental groups were formed: SO – sham-operated animals (without pathology); NC – negative control group (with cerebral ischemia, but lacking pharmacological support), and the group of rats receiving juglone and test-extract. The number of animals in a group was 20. Black walnut bark extract and juglone were administered per os 30 minutes after the simulation of ischemia and then once a day for 3 days. On the 4th day, the rats were tested in the Morris water maze, and the changes in the cerebral blood flow rate were assessed. After that, the rats were decapitated under chloral hydrate anesthesia (350 mg/kg intraperitoneally), venous blood and brain were taken and used as the analyzed biomaterial. In 10 animals from the group, the size of the brain necrosis zone was determined, in 10 remaining animals, changes in the activity of mitochondrial respiratory complexes, citrate synthase, and ATP level were assessed. The study design is shown in Fig.
Fresh citrated venous blood was centrifuged at 1000 g for 15 minutes to obtain serum, in which the concentrations of two parameters (lactic and pyruvic acids) were determined. The right hemisphere (ischemic) was cut off from the brain and homogenized in 10 animals from the group in phosphate-buffered saline (pH=7.4) in a ratio of 1:7 and used to assess the change in the size of the necrosis zone. In the remaining 10 animals, the right hemisphere was homogenized in an isolation medium (1 mmol EGTA + 215 mmol mannitol + 75 mmol sucrose + 0.1% BSA solution + 20 mmol HEPES, with pH of 7.2). For mitochondrial isolation, the resulting homogenate was centrifuged at 1100 g for 2 minutes. The resulting supernatant in the amount of 700 µl was transferred into Eppendorf tubes and mixed with 75 µl of 10% percol and centrifuged at 18000 g for 10 minutes. The precipitate was resuspended in 1 ml of the isolation medium and centrifuged for 5 minutes at 10000 g. This supernatant was used to determine changes in the activity of complexes of the mitochondrial respiratory chain, citrate synthase activity, and ATP concentration.
The study of the toxicity of the extract was carried out using the available method for studying the oral toxicity of chemical substances in an acute experiment – the ”Up and down” procedure. According to this protocol, two tests were conducted: limit testing and basic testing. The analysis and the LD50 calculation corresponded to the OECD Guidelines for the Testing of Chemicsla No. 425. According to these guidelines, the range of administered doses for the test-compounds was: 1.75; 5.5; 17.5; 55; 175; 550; 1750; 5000 mg/kg with a dose extension coefficient 3.2. The administration of the compounds was carried out fractionally with 1 hour time interval until the required dose was reached, according to the following scheme: the first animal receives the test objects at a dose of 1.75 mg/kg, if the animal survives, the administration of the compound continues in increasing order of doses until the 1st case of death is reported. After registering a fatal outcome, the next animal receives a lower dose of the test compounds than the previous one. The criteria for stopping the experiment were:
Cerebral ischemia was simulated by the method of irreversible occlusion of the middle cerebral artery. The course of the operation was the following: in anesthetized animals (chloral hydrate 350 mg/kg, intraperitoneally), on the depilated area below and to the right of the eye, the skin was dissected and the muscles were moved apart. Then the process of the zygomatic bone was removed and the skull was exposed. Next, a burr was used to make a trepanation hole above the intersection of the middle cerebral artery and the olfactory tract; the dura mater was removed, and the artery was electrocoagulated and then cut to avoid vessel recanalization, and the wound was sutured in layers. The suture was treated with an antiseptic solution Benzyldimethyl [3-myristoilamine propyl] ammonium chloride monohydrate (0.01% solution). Animals were left under a heating lamp until emergence from anasthesia (
The Morris water maze device is a water arena with a diameter of 150 cm with a wall height of 60 cm and a movable platform with a diameter of 10 cm (Open science, Russia). During the study, the unit was filled with water to the level of 50 cm, after which the water was stained. Before cerebral ischemia simulation, the rats were trained through the testing procedure: within 2 minutes, the animals were allowed to find a platform, provided no complete of the task; after that, the rats were moved to the platform for 10 sec., and the testing was repeated. The training lasted for 5 days. After simulating ischemia in similar conditions, the test was repeated. The latency period of reaching the platform in seconds and the distance that the animal covered until finding the platform in meters were recorded. The experiment was recorded and processed using the Minotaur software (Neurobiotics, Russia) with infrared monitoring of activity (
The cerebral blood flow rate was assessed in the middle cerebral artery basin in animals anesthetized with chloral hydrate (350 mg/kg, intraperitoneally). In rats, in the parietal region, the cranium was opened with the removal of the dura mater and arachnoid meninges, after which the ultrasonic Doppler sensor UZOP-010-01 with an operating frequency of 25 MHz was installed. A contact gel was used as a sound-conducting medium. The change in the rate of cerebral blood flow was determined in cm/sec using the MM-D-K-Minimax Doppler v.1.7 software. (Saint-Petersburg, Russia).
The size of the necrosis zone was determined by the triphenyltetrazolium method. The brain was removed, with the cerebellum cut off, and divided into the hemispheres. Both hemispheres were weighed, then separately homogenized and placed in cups with 10 ml of a 1% solution of triphenyltetrazolium chloride in phosphate buffer (pH=7.4). The sample was placed in a water bath for 20 minutes at 37 °C. Tne samples were centrifuged at 5000 rpm/10 min. Next, 3 ml of cooled chloroform was added to the supernatant and incubated for 15 minutes at 40 °C with periodic stirring. The resulting mixture was re-centrifuged, and the optical density of the chloroform extract of formazan was measured at 492 nm against pure chloroform. The calculation of the necrosis zone was expressed as a percentage of the total mass of the hemispheres by formula (1) (
(1),
where x is the size of the zone of necrosis as a percentage of the total mass of the brain; ε1 is the optical density of the sample with an intact hemisphere; ε2 is the optical density of the sample with a damaged hemisphere; M1 is the mass of the intact hemisphere; M2 is the mass of the damaged hemisphere.
The activity of the mitochondrial respiratory chain complexes I, II, IV, and V was studied by adding the corresponding oxidation substrates to the analyzed medium: pyruvate – 10 mmol/ml; malic acid – 1 mmol/ml; succinic acid – 10 mmol/ml; ascorbate – 2 mmol/ml; adenosinediphosphate – 1 mmol/ml; and N, N, N ‘, N’ tetramethyl-1,4-phenylenediamine (TMPD) – 0.5 mmol/ml (
Citrate synthase activity was determined according to the method described by
The concentration of lactate in blood serum was determined by the enzymatic reaction with the formation of quininomine, the concentration of which is proportional to the content of lactic acid in the sample. Incubation medium: phosphate buffer (pH 6.8), Pipes 50 mmol/L, 4-chlorophenol 6 mmol/L, AAP4 0.4 mmol/l, 2000 U/L lactoxydase, and U/L peroxidase. The volume of the test sample was 10 μl. Sampling was carried out at 500 nm. Calculation of the lactic acid content was carried out according to the formula (2) (
(2),
where Ex is absorbance of the test sample; E0 is absorbance calibration sample.
The content of pyruvic acid in blood serum was determined by a decrease in NADH in the lactate dehydrogenase reaction. Incubation medium: Good’s buffer 1000 μL, NADH 200 μL, and LDH (2000 U/L) 20 μl. The volume of the sample was 600 μl. Samples were measured at 340 nm. Calculation of the pyruvic acid concentration was carried out according to the formula (3) (
(3),
where Ex is absorbance of the test sample; E0 is absorbance calibration sample.
The ATP content in the brain supernatant of animals was assessed by enzyme-linked immunosorbent assay using species-specific reagent kits. Reagents were provided by Cloud Clone Corp. (USA). The assay progress was consistent with the kit manufacturer’s recommendations.
Statistical processing of the obtained results was performed using the STATISTICA 6.0 application software package (StatSoft, USA). Data were expressed as M (mean)±SEM. Comparison of means groups was carried out by the method of one-way analysis of variance with postprocessing Newman-Keuls test.
While testing the maximum permissible dose, it was found that when the extract of black walnut bark at a dose of 5000 mg/kg was administered to the animals, there was no death of mice. At the same time, no significant deviations of the general condition of the animals from the control group (n=4) were found. In this regard, based on the OECD Guidelines No. 425, the main testing was not started and the LD50 value of the test extract was accepted as a value of 5000 mg/kg (orally). At the same time, based on the literature data, it can be assumed that the effective dose for the test extract will be a dose of 1/100 of the LD50, which is 50 mg/kg (
While assessing the effect of the test extract on the change in the behavior of animals in the Morris water maze, it was found that in the NC group of rats, compared with the SO animals, there was an increase in the latency time of platform search (Fig.
Influence of the test extract of black walnut bark and juglone on changes in animal behavior in the Morris water maze test. Note: SO – sham-operated animals, NC – negative control, J – a group of animals that received juglone, JN – a group of animals that received the studied extract of black walnut bark, # – statistically significant relative to SO rats (Newman-Keuls test, p<0.05); * – statistically significant relative to NC rats (Newman-Keuls test, p<0.05).
While carrying out this block of experimental work, it was found that in the NC group of rats, the rate of cerebral blood flow (Fig.
Influence of the test extract and juglone on changes in cerebral blood flow rate in rats. Note: SO – sham-operated animals, NC – negative control, J – a group of animals that received juglone, JN – a group of animals that received the studied extract of black walnut bark, # – statistically significant relative to SO rats (Newman-Keuls test, p<0.05); * – statistically significant relative to NC rats (Newman-Keuls test, p<0.05).
At the same time, there was an increase in the concentration of lactate in the blood serum of NC animals and a decrease in the content of pyruvate (Table
Influence of the test extract of black walnut bark and juglone on the change in the concentrations of lactic and pyruvic acids in the blood serum of rats and brain necrosis zone area
Group | Lactic acid, mmoles/L | Pyruvic acid, µmoles/L | Necrosis zone area, % |
---|---|---|---|
SO | 1.2±0.04 | 125.6±8.27 | 0 |
NC | 6.8±0.05# | 65.9±13.29# | 35.9±2.469 |
J, 1 mg/kg | 4.2±0.06* | 87.2±14.88* | 28.7±2.971* |
JN, 50 mg/kg | 3.6±0.05* | 92.7±13.92* | 24.6±3.225* |
Evaluating the change in the activity of mitochondrial complexes (Fig.
Influence of the test extract of black walnut bark and juglone on changes in the mitochondrial respiratory complexes activity in the brain of rats. Note: SO – sham-operated animals, NC – negative control, J – a group of animals that received juglone, JN – a group of animals that received the studied extract of black walnut bark, # – statistically significant relative to SO rats (Newman-Keuls test, p<0.05); * – statistically significant relative to NC rats (Newman-Keuls test, p<0.05).
The activity of citrate synthase and the concentration of ATP (Table
Influence of the test extract of black walnut bark and juglone on changes in the citrate synthase activity and ATP concentration in the brain in rats
Group | ATP concentration, pg/ml | Citrate synthase activity, U/mg of protein |
---|---|---|
SO | 1594.2±78.645 | 4.1±0.659 |
NC | 691.4±90.622# | 1.8±0.142# |
J, 1 mg/kg | 956.4±54.005* | 2.5±0.821* |
JN, 50 mg/kg | 1002.4±93.285* | 2.9±0.287* |
To date, ischemic stroke remains one of the main problems of modern healthcare with a high level of disability and mortality. It has been found that it is possible to reduce the negative consequences of stroke through the use of neuroprotective agents (
As a result, elimination of energy deficit and restoration of cerebral hemodynamics contributed to a decrease in the area of brain necrosis and preservation of cognitive functions in rats, which indicates a high neuroprotective potential of the black walnut bark extract, comparable to juglone. In addition, the test extract was characterized by low systemic toxicity with LD50>5000 mg/kg, while juglone (as an individual compound) is a rather toxic compound. It has been found that juglone promotes the activation of apoptosis, both by caspase-dependent and caspase-independent mechanisms (
The study showed that a 40% ethanol extract of black walnut bark has a neuroprotective effect in a model of permanent right-sided middle cerebral occlusion in rats. Administration of the studied extract to animals at a dose of 50 mg/kg (1/100 of the LD50) promoted the restoration of the activity of mitochondrial complexes I-V, citrate synthase, increased the level of cerebral blood flow and the intensity of aerobic metabolic reactions, and reduced the size of the brain necrosis zone comparable to that of juglone. Thus, we can assume the relevance of the further study of 40% ethanol extract of black walnut bark as a means of neuroprotective action.
The authors declare no conflict of interests.
The study received no sponsorship.
Dmitry I. Pozdnyakov, PhD in Pharmacy, Associate Professor of Department of Pharmacology with Course of Clinical Pharmacology, e-mail: pozdniackow.dmitry@yandex.ru, ORCID ID https://orcid.org/0000-0002-5595-8182. Developing research design, conducting an experiment, and preparing the final draft of the manuscript.
Zhanna V. Dayronas, Doctor Habil of Pharmacy, Professor of Department of Pharmacognosy, Botany and Technology of Phytopreparations, e-mail: daironas@mail.ru, ORCID ID https://orcid.org/0000-0002-1274-4512. Preparing the studied extract and preparing the final draft of the manuscript
Denis S. Zolotych, PhD in Pharmacy, Associate Professor of Department of Pharmaceutical and Analytical Chemistry, e-mail: metranidazol@mail.ru, ORCID ID https://orcid.org/0000-0001-6314-080X. Statistical analysis and preparing the final draft of the manuscript.
Anastasya D. Geraschenko, PhD in Pharmacy, Associate Professor of Department of Pharmacology with Course of Clinical Pharmacology, e-mail: anastasiya_geraschenko@mail.ru, ORCID ID https://orcid.org/0000-0003-0294-2926. Experimenting and preparing the final draft of the manuscript.
Natalya B. Shabanova, PhD in Pharmacy, Associate Professor of Department of Pharmacology with Course of Clinical Pharmacology, e-mail: vahlushina05@yandex.ru, ORCID ID https://orcid.org/0000-0001-6281-1114. Experimenting and preparing the final draft of the manuscript.